vinblastine + prednisone + vincristine + rituximab

This is a multi-agent combination chemotherapy regimen composed of **vinblastine**, **prednisone**, **vincristine**, and **rituximab**. Each component has a distinct mechanism of action: - **Vinblastine** and **vincristine** are vinca alkaloids that inhibit microtubule assembly, blocking cell division and leading to apoptosis in rapidly dividing cells. - **Prednisone** is a synthetic corticosteroid that induces cell death in lymphoid malignancies through immunosuppression and anti-inflammatory pathways. - **Rituximab** is a chimeric monoclonal antibody directed against CD20, primarily expressed on B cells, causing complement-mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis of malignant B cells. This drug combination is designed to synergistically target lymphoid malignancies, utilizing distinct but complementary antineoplastic mechanisms.